

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

VOLUNTARY ANNOUNCEMENT

**PURCHASE OF SHARES IN THE COMPANY BY
THE CONTROLLING SHAREHOLDER**

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company has been informed by Ample Up Limited (“**Ample Up**”), a shareholder of the Company and a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (“**Fosun Pharma**”), that Ample Up and its subsidiaries (excluding the Company), plans to make on-market purchases of the Company’s shares (“**Shares**”) for not more than 1% of the total number of issued Shares within a period of six months from the date of this announcement.

On 24 August 2023, Ample Up made on-market purchase of 536,800 Shares at an average price of HK\$6.8046 per Share. As at 24 August 2023, Fosun Pharma, a controlling shareholder of the Company, through its wholly-owned subsidiaries, is interested in an aggregate of 332,448,000 Shares, representing approximately 71.14% of the issued share capital of the Company.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, 24 August 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as Executive Directors; Mr. Yifang WU and Ms. Rongli FENG as Non-Executive Directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as Independent Non-executive Directors.

* for identification purpose only